Alkem Laboratories enters into asset purchase agreement with AbbVie

31 Dec 2019 Evaluate

Alkem Laboratories has entered into an asset purchase agreement with AbbVie Inc., USA for acquisition of certain assets related to the active pharmaceutical ingredient, Dronabinol which include domain names and trademarks related to ‘Marinol’, New Drug Application registration with USFDA for Marinol, logos, patents designs, know how, technical and manufacturing instructions, inventory manufacturing equipment and such items.  The company shall own the NDA and associated assets and will use these to commercially exploit both Branded and Generic sales in US.

Alkem Laboratories is a leading Indian pharmaceutical company with global operations, engaged in the development, manufacture and sale of pharmaceutical and nutraceutical products. The company produces branded generics, generic drugs, active pharmaceutical Ingredients (APIs) and nutraceuticals, which it markets in India and International markets.

Alkem Laboratories Share Price

5689.30 77.65 (1.38%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×